Evaluating new ultrasound techniques for assessing placental health
Official title: Evaluation of Innovative Placental Imaging Techniques in Fetal Growth Restriction
Run by Carilion Clinic · NCT06861309 · Data updated 2026-11-12
This study is testing new ultrasound techniques to see if they can help tell the difference between healthy pregnancies and those with fetal growth issues.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 60 (estimated) |
| Sponsor | Carilion Clinic Academic / other |
| Locations | 1 site (Roanoke, Virginia) |
| Status | Recruiting |
| Started | April 23, 2025 |
| Main results expected | July 2026 |
| Study ends | November 2026 |
| Registry record updated | May 22, 2026 |
| Trial ID | NCT06861309 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are pregnant individuals aged 18 to 45 with singleton gestations between 18 to 26 weeks, who are at low risk for fetal growth restriction.
✕Probably not a fit
Patients with known risk factors for fetal growth restriction or those with multiple gestations may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the effectiveness of two advanced ultrasound technologies, quantitative ultrasound (QUS) and ultrafast power Doppler imaging (uPDI), in evaluating placental health and blood flow in singleton pregnancies. The primary objective is to differentiate between healthy pregnancies and those affected by fetal growth restriction (FGR). Secondary objectives include monitoring changes in ultrasound imaging over the course of pregnancy and identifying potential complications related to placental insufficiency. The study will utilize both experimental and FDA-approved ultrasound machines to gather data.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection of placental issues, potentially reducing risks associated with fetal growth restriction.
How similar studies have gone: While the use of ultrasound techniques for placental assessment is established, the specific combination of QUS and uPDI in this context is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Normal-Fetal-Weight Pregnancies Arm: Patient at least 18 to 45 years of age at screening * Normal-Fetal-Weight Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders or growth abnormalities * Normal-Fetal-Weight Pregnancies Arm: Low-risk aneuploidy screening, if performed * Normal-Fetal-Weight Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC) * Normal-Fetal-Weight Pregnancies Arm: Anatomical survey has been performed * Normal-Fetal-Weight Pregnancies Arm: Pregnancy without current fetal growth restriction (FGR) diagnosis * Normal-Fetal-Weight Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Patient at least 18 to 45 years of age at screening * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-anomalous, singleton gestation without suspected genetic disorders * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Low-risk aneuploidy screening, if performed * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Intention to deliver at Carilion Roanoke Memorial Hospital (CRMH) or Carilion New River Valley Medical Center (CNRVMC) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Anatomical survey has been performed * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Pregnancy diagnosed with fetal growth restriction (FGR) by estimated fetal weight \<10th centile or abdominal circumference measurements \<10th centile * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Subject willing and able to provide informed consent Note: Verify that the most recent version of the ICF was used to consent the subject Exclusion Criteria: * Normal-Fetal-Weight Pregnancies Arm: Multiple gestations * Normal-Fetal-Weight Pregnancies Arm: Known fetal anomaly affecting biometric measurements * Normal-Fetal-Weight Pregnancies Arm: Suspected fetal genetic disorder(s) * Normal-Fetal-Weight Pregnancies Arm: Suspected fetal infection(s) * Normal-Fetal-Weight Pregnancies Arm: Non-English or Spanish-speaking * Normal-Fetal-Weight Pregnancies Arm: Unstable housing or transportation * Normal-Fetal-Weight Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment. * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Multiple gestations * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Known fetal anomaly affecting biometric measurements * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal genetic disorder(s) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Suspected fetal infection(s) * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Non-English or Spanish-speaking * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Unstable housing or transportation * Fetal-Growth-Restricted (FGR) Pregnancies Arm: Any other criterion which, in the clinical judgement of the investigator, would make the subject unsuitable for study enrollment.
Where it's running
-
Carilion Clinic Maternal Fetal Medicine
Roanoke, Virginia, United States Recruiting
Study contacts
- Principal investigator: Megan D Whitham, MD — Carilion Clinic
- Study coordinator: Megan D Whitham, MD
- Email: mdwhitham@carilionclinic.org
- Phone: 540-985-9985
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
ASPIRE: Predicting Pregnancy Complications Using Blood and Eye Imaging
This study tests whether blood and eye imaging biomarkers can predict conditions like preeclampsia, fetal growth restriction, and gestational diabetes in first-time pregnant people carrying one baby.
-
Maternal insulin and fat metabolism in pregnancies at risk for preeclampsia and gestational diabetes
This project will try to see if insulin resistance and how the body burns fats early in pregnancy predict later preeclampsia or gestational diabetes in people at higher risk.
-
MI MOM: A web app to support healthy pregnancy and postpartum health
This study tests whether the MI MOM web app, used with support from friends and family, improves pregnancy and postpartum health for Medicaid-enrolled pregnant people compared to usual care.
-
Examining how aspirin metabolism relates to metabolic dysfunction in pregnant individuals at risk of preeclampsia
This study is trying to see how the way pregnant people process aspirin relates to their metabolic health and the health of their babies, especially for those at risk of preeclampsia.
-
Two-Door Doulas: Enhanced vs Standard Medicaid Doula Care in Pregnancy
This trial tests whether an enhanced, earlier, and more frequent doula support program helps pregnant people on Medicaid feel less depression and anxiety after birth compared with the standard Medicaid doula care in Florida.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.